Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose

View/ Open
Author
Byrareddy, Siddappa N
Shanmuganathan, Vivekanandan
Hemashettar, Girish
Rasmussen, Robert A
Brandstoetter, Tania
Mukhtar, Muhammad M
Yoon, John K
Novembre, Francis J
Villinger, Francois
Landucci, Gary
Forthal, Donald N
Ratcliffe, Sarah
Tuero, Iskra
Robert-Guroff, Marjorie
Polonis, Victoria R
Bilska, Miroslawa
Montefiori, David C
Johnson, Welkin E
Ertl, Hildegund C
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1186/1742-4690-11-8Metadata
Show full item recordCitation
Sholukh, A. M., S. N. Byrareddy, V. Shanmuganathan, G. Hemashettar, S. K. Lakhashe, R. A. Rasmussen, J. D. Watkins, et al. 2014. “Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.” Retrovirology 11 (1): 8. doi:10.1186/1742-4690-11-8. http://dx.doi.org/10.1186/1742-4690-11-8.Abstract
Background: A key goal for HIV-1 envelope immunogen design is the induction of cross-reactive neutralizing antibodies (nAbs). As AIDS vaccine recipients will not be exposed to strains exactly matching any immunogens due to multiple HIV-1 quasispecies circulating in the human population worldwide, heterologous SHIV challenges are essential for realistic vaccine efficacy testing in primates. We assessed whether polyclonal IgG, isolated from rhesus monkeys (RMs) with high-titer nAbs (termed SHIVIG), could protect RMs against the R5-tropic tier-2 SHIV-2873Nip, which was heterologous to the viruses or HIV-1 envelopes that had elicited SHIVIG. Results: SHIVIG demonstrated binding to HIV Gag, Tat, and Env of different clades and competed with the broadly neutralizing antibodies b12, VRC01, 4E10, and 17b. SHIVIG neutralized tier 1 and tier 2 viruses, including SHIV-2873Nip. NK-cell depletion decreased the neutralizing activity of SHIVIG 20-fold in PBMC assays. Although SHIVIG neutralized SHIV-2873Nip in vitro, this polyclonal IgG preparation failed to prevent acquisition after repeated intrarectal low-dose virus challenges, but at a dose of 400 mg/kg, it significantly lowered peak viremia (P = 0.001). Unexpectedly, single-genome analysis revealed a higher number of transmitted variants at the low dose of 25 mg/kg, implying increased acquisition at low SHIVIG levels. In vitro, SHIVIG demonstrated complement-mediated Ab-dependent enhancement of infection (C’-ADE) at concentrations similar to those observed in plasmas of RMs treated with 25 mg/kg of SHIVIG. Conclusion: Our primate model data suggest a dual role for polyclonal anti-HIV-1 Abs depending on plasma levels upon virus encounter.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905655/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879668
Collections
- HMS Scholarly Articles [17714]
Contact administrator regarding this item (to report mistakes or request changes)